An Introduction to Neuroimmunology
Neuroimmunology aims to understand the interactions of the immune and nervous systems. Neural targets involved in many aspects of homeostasis are affected by inflammatory cytokines. The most well-known autoimmune neurological disorder is multiple sclerosis, characterised by an inflammatory autoimmune attack on the myelin sheath and neurodegeneration. Neuroinflammation also plays a role in in Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, Huntington’s disease, stroke, chronic depression and schizophrenia. Neuroimmunology is also an important consideration in the design of neural implants. Further understanding of the balance between beneficial and pathological effects of the immune system on the neuronal system will facilitate the development of novel therapies.
Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Recent Advances on the Diagnosis and Management of Seronegative Neuromyelitis Optica Spectrum Disorder
touchREVIEWS in Neurology. 2024;20(1):Online ahead of journal publication
Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory autoimmune disease of the central nervous system (CNS) with a worldwide distribution.1 The first clinical description of NMOSD was made a century ago by Devic and Gault, who documented patients with monophasic and bilateral optic neuritis (ON) and myelitis.2 A few decades ago, NMOSD was considered a variant […]
Optimizing the management of patients with relapsing forms of MS: An update on emerging treatment options
Prof. Weber shares his expert perspectives on the optimal management of patients with relapsing forms of MS.
- Recognize processes for reliable and early identification of individuals with MS at high risk of transition to secondary progressive MS
- Discuss the evidence for B cells in the pathogenesis and progression of MS
- Appraise the efficacy and safety of approved and emerging therapeutic agents for relapsing forms of MS that target B cells
The complement system in NMOSD and MG: A target for therapeutic benefit?
Watch specialists in neurological disorders share their insights on the role of complement and complement therapeutics in patients with neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG).
- Describe the role of complement in the pathophysiology of NMOSD and MG
- Evaluate markers of complement activation as diagnostic and prognostic biomarkers in NMOSD and MG
- Discuss recently approved and experimental inhibitors of the complement system for the treatment of NMOSD and MG
Anthony Béhin, EAN 2023: Safety Profile Overview of Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases
Dr Anthony Béhin (University Hospitals Pitié Salpêtrière, Paris, France) discusses his abstract on the safety profile of anti-FcRn drugs, in particular efgartigimod, and anti-complement drugs in the treatment of IgG-mediated autoimmune diseases. The abstract ‘EPR-128 Safety Profile Overview of Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases’ was presented at the annual European Academy […]
A Rare Presentation of Steroid-responsive Encephalopathy Associated with Autoimmune Thyroiditis with Neuropsychiatric Symptoms: A Case Report
touchREVIEWS in Neurology. 2023;19(2):16-18
Case study Patient information A 42-year-old woman presented in the emergency department with acute onset whole-body myoclonic jerks for 1 day. On enquiry, the patient’s parents advised that she had a history of depression over the past 15 years. Intermittently, family members had also noticed aggressive and abusive behaviour. She had been evaluated and diagnosed […]
Highlights from EAN 2023!
Latest developments in neuromyelitis optica spectrum disorder: Diagnostics, treatments and patient-centred care
Three experts examine evidence-based approaches for early and accurate diagnosis, appropriate treatment selection and patient-centred care to mitigate the clinical burden of neuromyelitis optica spectrum disorder.
- Recall strategies that facilitate an early and accurate diagnosis of NMOSD
- Describe how evidence from clinical trials investigating current and emerging treatments for NMOSD informs clinical decision making
- Select individualized management plans for patients with NMOSD to reduce the patient-reported burden of symptoms
Individualizing long-term treatment and care in active MS: How are therapeutic sequencing options evolving to address unmet needs?
Two experts in MS explore the practicalities of therapeutic sequencing options in MS
- Evaluate factors guiding the use of high-efficacy DMTs in the management of active MS
- Summarize current approaches and safety considerations relating to DMT switching and sequencing in MS
- Appraise the use of DMTs in women of child-bearing age with MS, including considerations for family planning and implications during pregnancy and beyond
Michael Levy: Highlights from the 75th AAN Annual Meeting, 2023
Dr Michael Levy (Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA) provides his highlights from the 75th AAN Annual Meeting, 2023, in particular that this was the first year to have a myelin oligodendrocyte glycoprotein (MOG) antibody disease focus, with posters on two phase 3 trials, which are expected to be presented in 2026. Disclosures: […]